Patients with psoriatic arthritis (PsA) were found to be more likely to report musculoskeletal symptoms and dermatologic issues prior to initial PsA diagnosis.
Musculoskeletal symptoms and incidence of psoriasis may serve as predictors of psoriatic arthritis (PsA) diagnosis, according to study findings published in Arthritis Research & Therapy.
As a chronic inflammatory disease marked by a myriad of skin and musculoskeletal manifestations, there are 6 clinical domains of PsA, which include axial disorders, nail disease, skin disease, peripheral disease, enthesitis, and dactylitis, either alone or in combination.
Although timely diagnosis of PsA is vital to patient outcomes, researchers note that diagnostic delay is common for the condition, with a prior cross-sectional study finding that one-third of evaluated patients had to wait for more than 5 years to receive their diagnosis despite having consulted with numerous health care providers.
“A 6-month delay from PsA symptom onset to initial rheumatology consult may lead to joint erosion and damage,” cautioned the study authors. “ An increased awareness of the heterogeneity of PsA symptoms and diagnostic barriers may lead to a timely diagnosis.”
Seeking to better understand patient experiences and health events in the period prior to PsA diagnosis as a way to uncover potential predictors of PsA pathophysiology, they conducted a retrospective cohort study of diagnostic codes and provider type data derived from MarketScan claims data between January 2006 and April 2019.
In the analysis, adult patients who were enrolled in the database for 6 or more years before PsA diagnosis and who had greater than 2 PsA diagnoses 30 or more days apart were included (n = 13,661; mean [SD] age, 55.8 [12.6] years; 60.2% women). Matched controls (n = 26,729) were compared at a 2:1 ratio with patients with PsA, with health events (diagnoses and provider types) analyzed before PsA diagnosis and also stratified by presence of psoriasis.
Compared with controls, patients with PsA were indicated to receive more diagnosis codes for arthritis and dermatologic issues, including for osteoarthritis (OA; 47.8% vs 21.7%), rheumatoid arthritis (RA; 18.1% vs 2.3%), inflammatory polyarthropathy (IA; 17.6% vs 1.0%), and psoriasis (61.3% vs 1.9%).
Moreover, patients with PsA who did not have a prior psoriasis diagnosis were found to receive more diagnosis codes than controls for OA (52.5% vs 44.8%), RA (26.8% vs 12.6%), and IA (25.6% vs 12.5%).
Researchers noted that patients received a variety of diagnosis codes for their condition prior to the first PsA diagnosis code, suggesting potential misdiagnosis.
In the 6 years prior to PsA diagnosis, more than 10% of patients had coding for axial manifestations, nonspecific musculoskeletal manifestations, psoriasis, and/or skin manifestations. And when PsA was finally diagnosed, codes of nonspecific musculoskeletal manifestations, skin manifestations, axial manifestations, psoriasis, OA, and/or tendonitis/enthesitis were reported in more than 20% of patients.
“A sharp rise in psoriasis diagnoses was observed 6 months before PsA diagnosis,” added the study authors.
When evaluating types of providers in patients’ pathways to diagnosis, rheumatology consults were found to be more common in the final 6-month period immediately before the diagnosis of PsA (22.9 to 34.9%). Notably, diagnoses made prior to PsA diagnosis differed by the type of provider that patients saw:
“The clinical and economic burden associated with PsA will most likely impact disease management and medical and pharmacy policy formulation,” concluded the study authors. “Increased awareness and understanding of diagnostic barriers may lead to timelier diagnosis, cost savings, and appropriate intervention to improve outcomes.”
Reference
Ogdie A, Rozycki M, Arndt T, Shi C, Kim N, Hur P. Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis. Arthritis Res Ther. Published online October 1, 2021. doi:10.1186/s13075-021-02628-2
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen